Drug Profile
Interferon alpha 2b inhalation - Altum Pharmaceuticals/BetterLife Pharma
Alternative Names: AntiCovir; AP 003 - Altum Pharmaceuticals; Interferon alpha 2b inhalation - BetterLife Pharma; MM-003; recombinant human interferon alpha-2b - BetterLife Pharma; rhIFNa2b - BetterLife PharmaLatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Altum Pharmaceuticals; Unknown
- Developer Altum Pharmaceuticals; BetterLife Pharma; Pontifical Catholic University of Chile
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Interferon alpha-2 replacements; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections in China (Inhalation)
- 05 Aug 2022 Altum Pharmaceuticals completes phase I/II trials in COVID-2019 infections (In volunteers) in Chile (Inhalation) (NCT04988217)
- 29 Nov 2021 Phase-II clinical trials in COVID-2019 infections in Chile (Inhalation)